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Conjunctival melanoma with orbital
invasion and liver metastasis managed
with systemic immune checkpoint
inhibitor therapy
Michael Chang1, Sara E Lally1, Lauren A Dalvin1,2,
Marlana M Orloff3, Carol L Shields1
A 60‑year‑old Caucasian female was referred for biopsy‑proven
amelanotic orbito‑conjunctival melanoma. Map biopsies revealed
Access this article online
Quick Response Code:

Website:
www.ijo.in
DOI:
10.4103/ijo.IJO_663_19
PMID:
*****

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson
University, Philadelphia, PA, 2Department of Ophthalmology, Mayo
Clinic, Rochester, MN, 3Department of Medical Oncology, Thomas
Jefferson University, Philadelphia, PA, USA
1

Correspondence to: Dr. Carol L Shields, Ocular Oncology Service,
840 Walnut Street, Suite 1440, Philadelphia ‑ 19107, PA, USA.
E‑mail: carolshields@gmail.com
Received: 02-Apr-2019
Accepted: 14-Jun-2019

Revision: 04-May-19
Published: 22-Nov-2019

2071

10. Vivian AJ, Ellison DW, McGill JI. Ocular melanomas in xeroderma
pigmentosum. Br J Ophthalmol 1993;77:597‑8.
11. El‑Hafrawi H, Mortada A. Ocular manifestations of xeroderma
pigmentosum. Br J Dermatol 1965;77:261‑76.
12. Rizvi SAR, Amitava AK, Mehdi G, Sharma R, Shahid M. Orbital
amelanotic melanoma in xeroderma pigmentosum: A rare
association. Indian J Ophthalmol 2008;56:421‑3.
13. Caso ER, Marcos AA, Morales M, Belfort RN. Simultaneous
squamous cell carcinoma and malignant melanoma of the
conjunctiva in a teenager with xeroderma pigmentosum: Case
report. Indian J Ophthalmol 2019;67:1190‑2.

residual invasive melanoma on the deep tarsal margin at the
site of previous surgery. Repeat excisions were required after
recurrence was detected following 3 months and 7 months.
Positron emission tomography scan detected liver metastasis
and additional orbito‑conjunctival melanoma recurrence.
Biomarker testing showed NRAS mutation without BRAF
or c‑KIT mutations and without PD‑L1 expression. Systemic
checkpoint inhibitor therapy was initiated with regression of
both the orbito‑conjunctival melanoma and liver metastasis.
Invasive, non resectable orbito‑conjunctival melanoma with liver
metastasis can demonstrate a response to systemic checkpoint
inhibitor therapy.
Key words: Checkpoint inhibitor, conjunctiva, eye, melanoma,
tumor

Conjunctival melanoma is a rare tumor with an incidence of
0.54 per million.[1] This malignancy is typically managed with
wide surgical resection using the “no touch” technique.[1]
In a study of 382 cases by Shields et al., an estimated 59%
of treated cases showed recurrence or new growth after
10 years and 19% demonstrated metastases. [2] Factors
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predictive of metastasis and disease‑related death included
orbital invasion, often requiring exenteration. More recently,
immune checkpoint inhibitors, a form of immunotherapy,
have been associated with improved survival for various
malignancies, including cutaneous melanoma.[3] Herein, we
present a case of recurrent orbito‑conjunctival melanoma
with metastasis that responded to immune checkpoint
inhibitors.

Case Report
A 60‑year‑old Caucasian female with a 30‑pack‑year smoking
history and family history of cutaneous melanoma presented
with a left upper tarsal conjunctival melanoma with orbital
invasion, previously managed elsewhere with orbitotomy.
Histopathology confirmed amelanotic melanoma arising from
primary acquired melanosis and with positive margins.
On our examination, visual acuity was 20/20 in both eyes
(OU) with a normal anterior segment in the right eye (OD).
The left eye (OS) demonstrated well‑healed biopsy sites on the
upper tarsal conjunctiva with no visible mass. Funduscopic
examination was normal OU. Given positive margins on
the previous biopsy, repeat map biopsies, and extensive
cryotherapy were performed. Histopathology revealed a small
focus of residual melanoma that showed an NRAS mutation,
but no BRAF or c‑KIT mutations. PD‑L1 expression was not
detected.
Three months later, melanoma recurrence [Fig. 1a]
was detected in the anterior orbit on magnetic resonance
imaging (MRI) [Fig. 1b] and was managed surgically. Four
months later, further recurrence was documented and
histopathologically confirmed. Sentinel lymph node mapping
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Figure 1: Recurrent orbito‑conjunctival melanoma in a 60‑year‑old
female appearing as (a) a palpable mass in the dermis and confirmed
on (b) magnetic resonance imaging (MRI) as an enhancing mass
along the superolateral aspect of the orbit. Following systemic immune
checkpoint inhibitor therapy (c) the palpable mass resolved and the
(d) MRI showed no evident tumor at 7 months
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and biopsy were negative for regional metastasis. Ocular
stereotactic radiotherapy was planned, but later withheld
owing to patient preference for vision preservation and
presence of metastasis seen as a hypermetabolic liver lesion on
positron emission tomography, confirmed with MRI [Fig. 2a].
Given the rapid pace of recurrence and with metastasis,
systemic checkpoint inhibitor therapy was considered. Variable
treatment efficacy and possible side effects were discussed. The
patient agreed to proceed and was started with multi‑agent
ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) for 2 cycles.
Following two cycles of the combination, she experienced
grade 2/3 hepatitis. She was then switched to single‑agent
nivolumab (240 mg every 2 weeks for 2 cycles and 480 mg
every 4 weeks for 1 cycle). She then developed infusion
reaction to nivolumab and was switched to single‑agent
pembrolizumab (200 mg every 3 weeks for 9 cycles).
After 14 cycles of immunotherapy, the orbito‑conjunctival
melanoma [Fig. 1c and d] and liver metastasis [Fig. 2b] showed
response on MRI and remained stable at 2 years.

Discussion
The immune system combats cancer by recognizing and
destroying tumor cells.[3] Tumor cells, however, can evolve to
evade immune recognition and killing.[3] Systemic immune
checkpoint inhibitors cause increased activation of the immune
system by targeting cytotoxic T‑lymphocyte antigen‑4,
programmed death protein (PD‑1), or programmed death
ligand‑1 (PD‑L1), to release inhibition on T cell activity.[3,4]
Thereby, these medications promote and augment the ongoing
immunologic response against malignant cells.[3,4]
Treatment of advanced and metastatic melanoma is
dependent on tumor subtype and genetic profile.[5] There are
no current targeted therapies approved for NRAS‑mutated
cutaneous melanomas. However, immune checkpoint
inhibitor therapies are considered first‑line treatment for
metastatic melanoma.[5] Given genetic similarities to cutaneous
melanoma, immune‑based treatments have been attempted
for conjunctival melanoma with metastasis as well.[3,6] Sagiv
et al. reported two cases of recurrent conjunctival melanoma
with metastasis successfully treated with systemic PD‑1
inhibitors (nivolumab and pembrolizumab).[6] Both patients
experienced a reduction in tumor size (one with complete
resolution) after 6 cycles of systemic therapy. Our patient, who
presented with NRAS‑positive, orbito‑conjunctival melanoma,
had similar results with a resolution of orbito‑conjunctival mass
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Figure 2: There was additional (a) liver metastasis on magnetic
resonance imaging (MRI) appearing as low signal that (b) responded
and remained regressed to systemic immune checkpoint inhibitor
therapy at 2 years
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and regression of liver lesion following 14 cycles of systemic
immunotherapy, in spite the absence of PD‑L1 expression by
the tumor.

Conclusion
In summary, we present a case of recurrent orbito‑conjunctival
melanoma with metastasis that showed regression following
systemic immune checkpoint inhibitor therapy. Larger studies
with advanced and metastatic conjunctival melanoma are
needed to assess long‑term outcomes and potential predictors
of response.
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treatment with 60-mg oral cobimetinib daily for 21 days/7 day
off in combination with 960 mg vemurafenib twice daily. The
patient had symptoms of blurred vision and photophobia in
his right eye. A slit-lamp examination revealed bilateral central
corneal stromal opacity and epithelial microcystic edema
Involvement was more severe in the right eye compared with
the left eye. Fourteen days after the first visit, the patient’s
symptoms and slit-lamp findings were largely resolved. We
suggest that endothelium pump failure was involved in this
acute corneal decompensation case similar to the mechanism in
retinal pigment epithelium.
Key words: Corneal decompensation, cobimetinib, MEK inhibitor

Malignant melanoma is a steadily increasing, significant
health problem. It is a dangerous form of skin tumor that
causes 90% of skin cancer‑related mortality.[1] At diagnosis,
metastases are present in approximately 2–5% of patients.[2] The
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